Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone, thiamine, and ascorbic acid supplementation in septic shock
IRCT20160901029640N2Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of hydrocortisone, thiamine and ascorbic acid in septic shock and sepsis (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: 28-day mortality rate. Started Nov 2019; status: completed.
02
Drugs
hydrocortisonethiamineascorbic acid
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on IRCT20160901029640N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160901029640N2.